Cellipont Bioservices and Xiogenix Partner on Advanced Filling Systems

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Cellipont Bioservices, a contract development and manufacturing organization (CMDO) that provides services for cell therapies such as process development, analytical services, and large-scale commercial manufacturing, and Xiogenix, a biotechnology company, announced on Dec. 10, 2024 that the companies have entered into a partnership that allows Cellipont’s clients to access Xiogenix’ Ares X20 fill/finish system. The Ares X20 is designed for cell and gene therapy production and offers precise temperature control, automated formulation, high-throughput, and the ability to process multiple containers in fewer than five minutes.

“This partnership with Xiogenix marks another significant milestone for Cellipont Bioservices,” said Darren Head, CEO of Cellipont Bioservices, in a press release (1). “We are committed to adopting advanced technologies that drive innovation and excellence in biopharmaceutical manufacturing. Through this collaboration with Xiogenix, we offer our clients access to advanced fill-and-finish system, enhancing our service offerings and delivering superior solutions.”

“We are thrilled to partner with Cellipont Bioservices to bring our Ares X20 fill and finish system to a broader range of clients,” said Rachel Bahr, CEO of Xiogenix, in the release. “This collaboration aligns with our mission to provide innovative solutions that enhance the efficiency and reliability of biopharmaceutical manufacturing. We look forward to seeing the positive impact this partnership will have on the industry.”

This is the second agreement Cellipont has made at the end of 2024. In October, the company announced an agreement with Mongoose Bio, a clinical-stage biopharmaceutical company developing T-cell-based therapies for solid cancers. Under that agreement, Cellipont will manufacture Mongoose Bio’s autologous MGB-001 T-cell receptor (TCR)-T cell therapy program. The MGB-001 targets that are highly immunogenic and broadly expressed in many solid tumors.

“Unlike other TCRs on the market or in development, ID/validation of this TCR epitope was rigorously selected from among an unbiased pool of 1000s of well-curated MHC [major histocompatibility complex]-eluted peptides, empirically validated, and clinically annotated to target pan-cancers. This therapy is built upon 17 years of pioneering work by founder Dr. Cassian Yee at his lab at the University of Texas MD Anderson Cancer Center (MDACC),” the companies stated in a press release (2).

“We’re pleased to be partnering with Mongoose Bio on their MGB-001 TCR-T Cell Therapy program. “We look forward to collaborating and working with their team to deliver this novel cell therapy to cancer patients,” said Mike O’Mara, COO of Cellipont Bioservices, in the release (2).

“Cellipont is a strong partner for us and has excellent manufacturing capabilities to support advancing our lead candidate MGB-001 into the clinic,” said Neil Warma, president and CEO of Mongoose Bio, in the release (2). “Our TCR-T therapies have the potential to transform the treatment of cancer and with Cellipont’s team of experts on board, we are on target to bring this very promising therapy to patients who have failed approved, front-line therapies in multiple tumor indications.”

References

1. Cellipont Bioservices and Xiogenix. Cellipont Bioservices and Xiogenix Announce Strategic Partnership to Enhance Client Access to Advanced Filling Systems. Press Release. Dec. 10, 2024.
2. Cellipont Bioservices. Cellipont Bioservices and Mongoose Bio Sign Agreement to Advance MGB-001, its Lead TCR-T therapy, towards the Clinic for Multiple Cancers. Press Release. Oct. 8, 2024.